Early prediction of local control in head and neck cancer after chemoradiotherapy by FDG-PET

Nuclear Medicine Communications

Volumn 32, Issue 8, 2011, Pages 684-689

  Hoshikawa, Hiroshi ^a   Kishino, Takehito ^a   Nishiyama, Yoshihiro ^b   Yamamoto, Yuka ^b   Yonezaki, Masafumi ^a   Mori, Nozomu ^a  

^a KAGAWA UNIVERSITY   (Japan)

^b KAGAWA UNIVERSITY   (Japan)

Author keywords

2 deoxy 2 18F fluoro D glucose positron emission tomography; chemoradiotherapy; head and neck; standardized uptake value; therapeutic outcome

Indexed keywords

CISPLATIN; DOCETAXEL; FLUORODEOXYGLUCOSE F 18; FLUOROURACIL; NEDAPLATIN;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CLINICAL ARTICLE; CONTINUOUS INFUSION; FEMALE; FOLLOW UP; HEAD AND NECK CARCINOMA; HUMAN; LYMPH NODE METASTASIS; MALE; POSITRON EMISSION TOMOGRAPHY; PREDICTIVE VALUE; PROGNOSIS; SENSITIVITY ANALYSIS; SQUAMOUS CELL CARCINOMA; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANALYSIS OF VARIANCE; FEMALE; FLUORODEOXYGLUCOSE F18; HEAD AND NECK NEOPLASMS; HUMANS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; POSITRON-EMISSION TOMOGRAPHY; RETROSPECTIVE STUDIES; TIME FACTORS; TREATMENT OUTCOME;

EID: 79960000116     PISSN: 01433636     EISSN: 14735628     Source Type: Journal    
DOI: 10.1097/MNM.0b013e328346f02c     Document Type: Article

References (26)

1. Forastiere AA, Goepfert H, Maor M, Pajak TF, Weber R, Morrison W, et al. Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N Engl J Med 2003; 349:2091-2098. (Pubitemid 37464533)
2. Denis F, Garaud P, Bardet E, Alfonsi M, Sire C, Germain T, et al. Final results of the 94-01 French head and neck oncology and radiotherapy group randomized trial comparing radiotherapy alone with concomitant radiochemotherapy in advanced-stage oropharynx carcinoma. J Clin Oncol 2004; 22:69-76. (Pubitemid 41095116)
3. Bourhis J, Eschwege F. Radiotherapy-chemotherapy combinations in head and neck squamous cell carcinoma: overview of randomized trials. Anticancer Res 1996; 16:2397-2402. (Pubitemid 26325422)
4. Munro AJ. An overview of randomised controlled trials of adjuvant chemotherapy in head and neck cancer. Br J Cancer 1995; 71:83-91.
5. Adelstein DJ, Li Y, Adams GL, Wagner H Jr, Kish JA, Ensley JF, et al. An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer. J Clin Oncol 2003; 21:92-98.
6. Kitagawa Y, Sano K, Nishizawa S, Nakamura M, Ogasawara T, Sadato N, et al. FDG-PET for prediction of tumour aggressiveness and response to intra-arterial chemotherapy and radiotherapy in head and neck cancer. Eur J Nucl Med Mol Imag 2003; 30:63-71. (Pubitemid 36692894)
7. McCollum AD, Burrell SC, Haddad RI, Norris CM, Tishler RB, Case MA, et al. Positron emission tomography with 18F-fluorodeoxyglucose to predict pathologic response after induction chemotherapy and definitive chemoradiotherapy in head and neck cancer. Head Neck 2004; 26:890-896. (Pubitemid 39299309)
8. Yao M, Graham MM, Smith RB, Dornfeld KJ, Skwarchuk M, Hoffman HT, et al. Value of FDG PET in assessment of treatment response and surveillance in head-and-neck cancer patients after intensity modulated radiation treatment: a preliminary report. Int J Radiat Oncol Biol Phys 2004; 60:1410-1418. (Pubitemid 39610495)
9. Isles MG, McConkey C, Mehanna HM. A systematic review and metaanalysis of the role of positron emission tomography in the follow up of head and neck squamous cell carcinoma following radiotherapy or chemoradiotherapy. Clin Otolaryngol 2008; 33:210-222. (Pubitemid 351799005)
10. Ware RE, Matthews JP, Hicks RJ, Porceddu S, Hogg A, Rischin D, et al. Usefulness of fluorine-18 fluorodeoxyglucose positron emission tomography in patients with a residual structural abnormality after definitive treatments for squamous cell carcinoma of the head and neck. Head Neck 2004; 26:1008-1017. (Pubitemid 39601219)
11. Greven KM, Williams DW III, Frederick McGuirt W Sr, Harkness BA, D'Agostino RB Jr, Keyes JW Jr, et al. Serial positron emission tomography scans following radiation therapy of patients with head and neck cancer. Head Neck 2001; 23:942-946. (Pubitemid 32977536)
12. Conessa C, Foehrenbach H, Herve S, Poncet J. FDG-PET scan in local follow-up of irradiated head and neck squamous cell carcinomas. Ann Otol, Rhinol Laryngol 2004; 113:628-635. (Pubitemid 39031106)
13. Koike I, Ohmura M, Hata M, Takahashi N, Oka T, Ogino I, et al. FDG-PET scanning after radiation can predict tumor regrowth three months later. Int J Radiat Oncol Biol Phys 2003; 57:1231-1238. (Pubitemid 37443959)
14. Hoshikawa H, Mitani T, Nishiyama Y, Yamamoto Y, Ohkawa M, Mori N. Evaluation of the therapeutic effects and recurrence for head and neck cancer after chemoradiotherapy by FDG-PET. Auris Nasus Larynx 2009; 36:192-198.
15. Sobin LH, Wittecind C. TNM classification of malignant tumors. 6th ed. New York: Wiley-Liss; 2002.
16. Lonneux M, Lawson G, Ide C, Bausart R, Remacle M, Pauwels S. Positron emission tomography with fluorodeoxyglucose for suspected head and neck tumor recurrence in the symptomatic patient. Laryngoscope 2000; 110:1493-1497.
17. Andrade RS, Heron DE, Degirmenci B, Filho PAA, Branstetter BF, Seethala RR, et al. Posttreatment assessment of response using FDG-PET/ CT for patients treated with definitive radiation therapy for head and neck cancers. Int J Radiat Oncol Biol Phys 2006; 65:1315-1322. (Pubitemid 44425218)
18. Yao M, Smith RB, Graham MM, Hoffman HT, Tan H, Funk GF, et al. The role of FDG PET in management of neck metastasis from head-and-neck cancer after definitive radiation treatment. Int J Radiat Oncol Biol Phys 2005; 63:991-999. (Pubitemid 41505274)
19. Inohara H, Enomoto K, Tomiyama Y, Higuchi I, Inoue T, Hatazawa J. Impact of FDG-PET on prediction of clinical outcome after concurrent chemoradiotherapy in hypopharyngeal carcinoma. Mol Imag Biol 2010; 12:89-97.
20. Porceddu SV, Jarmolowski E, Hicks RJ, Ware R, Weih L, Rischin D, et al. Utility of positron emission tomography for the detection of disease in residual neck nodes after (chemo)radiotherapy in head and neck cancer. Head Neck 2005; 27:175-181. (Pubitemid 40315765)
21. Schoder H, Fury M, Lee N, Kraus D. PET monitoring of therapy response in head and neck squamous cell carcinoma. J Nucl Med 2009; 50:74-88.
22. Ryan WR, Fee WE Jr, Le Q, Pinto HA. Positron-emission tomography for surveillance of head and neck cancer. Laryngoscope 2005; 115: 645-650. (Pubitemid 40530014)
23. Quon A, Fischbein NJ, McDougall IR, Le Q, Loo BW Jr, Pinto H, et al. Clinical role of 18F-FDG PET/CT in the management of squamous cell carcinoma of the head and neck and thyroid carcinoma. J Nucl Med 2007; 48:58-67.
24. Horiuchi C, Taguchi T, Yoshida T, Nishimura G, Kawakami M, Tanigaki Y, et al. Early assessment of clinical response to concurrent chemoradiotherapy in head and neck carcinoma using fluoro-2-deoxy-D-glucose positron emission tomography. Auris Nasus Larynx 2008; 35:103-108.
25. Malone JP, Gerberi MAT, Vasireddy S, Hughes LF, Rao K, Shevlin B, et al. Early prediction of response to chemoradiotherapy for head and neck cancer: reliability of restaging with combined positron emission tomography and computed tomography. Arch Otolaryngol Head Neck Surg 2009; 135:1119-1125.
26. Goerres GW, Schmid DT, Bandhauer F, Huguenin PU, Von Schulthess GK, Schmid S, et al. Positron emission tomography in the early follow-up of advanced head and neck cancer. Arch Otolaryngol Head Neck Surg 2004; 130:105-109. (Pubitemid 38095439)